<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of progressive <z:hpo ids='HP_0011010'>chronic</z:hpo> hematopoietic disorders, usually presenting as <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> or cytopenia, with an approximately 25% risk of progression toward <z:hpo ids='HP_0011009'>acute</z:hpo> myeloid leukaeima (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and no proven curative treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Novel biological treatment strategies targeting both the malignant blood cell and its microenvironment can overcome resistance to current therapies, and represent a promising treatment paradigm for improving patient outcome </plain></SENT>
<SENT sid="2" pm="."><plain>Many of these agents have multiple biologic activities </plain></SENT>
<SENT sid="3" pm="."><plain>The objective of this article is to present a comparative review of classification systems in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and to discuss the evolving trends in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (immunosuppresive therapy, immunomodulatory drugs, <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi>, <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi>, epigenetic therapy) </plain></SENT>
</text></document>